Covid-19 Group 1 Patients Monoclonal antibodies for patients hospitalised due to COVID-19 (977)


exp date isn't null, but text field is


Guidance for use in GGC

Neutralising monoclonal antibodies (nMAB) bind to specific sites on the spike protein of the SARSCoV-2 virus particle, blocking its entry into cells and therefore inhibiting its replication.

There is currently NO nMAB suitable for standard care treatment in Group 1 patients due to the predominance of the omicron variant, >90% of GGC cases

The following nMABs have conditional marketing authorisation for use in the treatment of COVID-19 in the UK.

  • Sotrovimab (Xevudy®) is an nMAB that both blocks viral entry into healthy cells and clears cells infected with SARS-CoV-2.
  • Casirivimab and imdevimab (Ronapreve®) is not effective against omicron variant so not currently used in GGC.

Sotrovimab is not currently commissioned for treatment of Group 1 patients. Group 1 patients (including pregnant patients) may be considered for treatment with sotrivimab within the RECOVERY Clinical Trial only. Please contact the following Principle Investigators and the Clinical Research Facility to discuss

QEUH Prof Malcolm Sim
Prof Kevin Blyth
GRI Dr Kathryn Puxty
RAH Dr Alasdair Corfield
IRH Dr Azharuddin Mohammed
RHC (patients aged 12-16) Paediatric ID Consultant On-Call
Clinical Research Facility Teams [email protected]


Use the button below to access this resource item.

Access this resource


Acute / All Inpatient
Board Wide
Medicines / Pharmacy

Last reviewed: 19 January 2022

Next review: 23 December 2022

Author(s): Samantha Carmichael

Version: 2 author version 4.0

Author Email(s): [email protected]

Approved By: Covid-19 Tactical Group (Acute)

Document Id: 977